Vaccine Immunotherapy Trial for Newly Diagnosed Glioblastoma
A multicenter study now open at UCSF tests adding a novel tumor-derived dendritic cell vaccine to standard of care therapy
As part of a new randomized phase 2 clinical trial now open through the UCSF Brain Tumor Center’s immunotherapy program, patients newly diagnosed with glioblastoma will receive DOC1021, a personalized vaccine designed to stimulate an immune response against the tumor cells, alongside standard-of-care chemoradiation or standard-of-care alone.
The vaccine trains the patient’s own dendritic cells to target the cancer cells. Dendritic cells are immune cells that regulate the immune response by recognizing and then presenting antigens to the T cells. Using a sample of the patient’s tumor collected during surgery, researchers can load dendritic cells with tumor-specific antigens, which then program the T cells to destroy the cancer.
“Our goal is to determine the efficacy of this new vaccine, and this study’s randomized design will help us clearly determine whether patients may benefit from adding this immunotherapy to the standard of care for glioblastoma,” said Thomas Nelson, MD, a UCSF neuro-oncologist and the principal investigator for this trial.
Developing immunotherapies that successfully retrain the immune system to attack glioblastoma has proven challenging because there isn’t a single antigen present on all brain tumor cells that distinguishes them from the surrounding brain tissue. Rather than focus on one antigen, this vaccine uses a mixture of antigens extracted from a patient’s own tumor called MHC class I and II antigens. This novel approach shows the T cells how to target the tumor cells based on a much broader set of the many antigens that they express, generating a longer-lasting immune response.
“Glioblastomas can look very different from one patient to another,” Thomas said, “so there’s a real need to develop more personalized treatment strategies for patients right from their initial diagnosis.”
The vaccine will be given to trial participants near the deep cervical lymph nodes in the neck after standard radiation therapy to help the engineered dendritic cells better reeducate the T cells that normally learn what brain-specific antigens look like and traffic across the blood-brain barrier. This strategy is meant to promote a stronger immune response.
In addition to studying the vaccine’s safety profile and its impact on overall survival, Thomas and his colleagues are also collecting post-treatment blood samples to explore how well it’s stimulating the immune system.
Since the dendritic cell vaccine is made from their tumor, patients who are newly diagnosed with glioblastoma need to have a tumor in a location that can be nearly or completely removed during surgery to be eligible for this trial. Their eligibility will be confirmed for up to 10 days after surgery at UCSF.